Clearside Biomedical (NASDAQ:CLSD) slumps 20% premarket on light volume in response to its announcement of Phase 2 data on the combination of CLS-TA (triamcinolone acetonide) and Regeneron Pharmaceuticals’ EYLEA (aflibercept) in patients with diabetic macular edema.
The company says the study met the primary endpoint of mean improvement in best corrected visual acuity from baseline to month 6 as measured by a scale called ETDRS. The average score in the treatment group was 12.3 ETDRS letters compared to 13.5 ETDRS letters in the EYLEA alone arm, however.
The data analysis is ongoing. Detailed results will be submitted for presentation at a future medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.